NxStage System One with NxView
Fresenius Medical Care Renal Therapies Group, LLC · Decision date May 15, 2026
What did the FDA decide?
FDA records K252377 as a 510(k) premarket notification, with a decision dated May 15, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- May 15, 2026
Regulatory record facts
- Identifier
- K252377
- Regulatory pathway
- 510(k) premarket notification
- Product code
- KDI
- Decision code
- SESE
- Decision date
- May 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dialyzer, High Permeability With Or Without Sealed Dialysate System.
- Product code
- KDI
- FDA device class
- 2
FDA decision timeline
K252377 received
Application receipt date recorded by FDA.
K252377 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KDI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
multiFiltratePRO SystemK261203 | Fresenius Medical Care Renal Therapies Group, LLC | 510(k) clearance | Oct 19, 2026 | FDA |
| Fresenius Medical Care Renal Therapies Group, LLC | 510(k) clearance | Jul 24, 2026 | FDA | |
ELISIO-HK260533 | Nipro Medical Corporation | 510(k) clearance | Mar 19, 2026 | FDA |
| Fresenius Medical Care Renal Therapies Group, LLC | 510(k) clearance | Feb 10, 2026 | FDA | |
| Outset Medical, Inc. | 510(k) clearance | Jan 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fresenius Medical Care Renal Therapies Group, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Waltham, MA
Sources and methodology
- Original FDA record: K252377
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


